Vianello, Clara
(2026)
Study of the role of microRNAs as circulating biomarkers in hepatocellular carcinoma, [Dissertation thesis], Alma Mater Studiorum Università di Bologna.
Dottorato di ricerca in
Sport, salute e benessere, 38 Ciclo.
Documenti full-text disponibili:
Abstract
Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related death worldwide. Although immunotherapy has revolutionized HCC management, sorafenib and lenvatinib remain first-line options for advanced-HCC, particularly in immunotherapy-ineligible patients. Transarterial chemoembolization (TACE) is recommended for intermediate-HCC stages. However, acquired resistance limits treatment efficacy, and the lack of predictive biomarkers remains an unmet clinical need.
Despite the well-known role of microRNA in HCC progression, metabolic reprogramming and drug response, the mechanisms driving sorafenib and TACE resistance remain poorly understood. Furthermore, while CXCL3, miR-30e-3p, and miR-22 are emerging as potential therapeutic targets, their predictive role is not yet fully elucidated.
My thesis project aimed at evaluating the predictive potential of circulating miR-22 in response to TACE and sorafenib treatment in intermediate- and advanced-stage HCC patient cohorts, respectively. In addition, my PhD project aimed at assessing the predictive value of the miR-30e-3p/CXCL3 axis in the early development of sorafenib resistance in HCC patients.
Firstly, I demonstrated CXCL3 targeting by miR-30e-3p in HCC, reporting its effect in sorafenib resistance in the DEN-HCC rat model. I evaluated CXCL3 and miR-30e-3p as potential circulating biomarkers of sorafenib response in HCC patients ongoing sorafenib treatment. Furthermore, I characterized miR-22 as a serum biomarker predictive of sorafenib response in a cohort of sorafenib-treated HCC patients and evaluated miR-22 effects in the DEN-HCC rat model. Moreover, I reported miR-22 as a promising circulating biomarker of TACE response. I also demonstrated WEE1 targeting by miR-22 and the involvement of miR-22/WEE1 axis in cell proliferation, apoptosis and DNA damage following doxorubicin treatment under hypoxia-like conditions.
Collectively, these data highlight the potential role of CXCL3, miR-30e-3p and miR-22 as circulating biomarkers of sorafenib response. Furthermore, miR-22 emerged as an early circulating biomarker of TACE nonresponse while the miR-22/WEE1 axis represents an interesting therapeutic target for combined strategies.
Abstract
Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related death worldwide. Although immunotherapy has revolutionized HCC management, sorafenib and lenvatinib remain first-line options for advanced-HCC, particularly in immunotherapy-ineligible patients. Transarterial chemoembolization (TACE) is recommended for intermediate-HCC stages. However, acquired resistance limits treatment efficacy, and the lack of predictive biomarkers remains an unmet clinical need.
Despite the well-known role of microRNA in HCC progression, metabolic reprogramming and drug response, the mechanisms driving sorafenib and TACE resistance remain poorly understood. Furthermore, while CXCL3, miR-30e-3p, and miR-22 are emerging as potential therapeutic targets, their predictive role is not yet fully elucidated.
My thesis project aimed at evaluating the predictive potential of circulating miR-22 in response to TACE and sorafenib treatment in intermediate- and advanced-stage HCC patient cohorts, respectively. In addition, my PhD project aimed at assessing the predictive value of the miR-30e-3p/CXCL3 axis in the early development of sorafenib resistance in HCC patients.
Firstly, I demonstrated CXCL3 targeting by miR-30e-3p in HCC, reporting its effect in sorafenib resistance in the DEN-HCC rat model. I evaluated CXCL3 and miR-30e-3p as potential circulating biomarkers of sorafenib response in HCC patients ongoing sorafenib treatment. Furthermore, I characterized miR-22 as a serum biomarker predictive of sorafenib response in a cohort of sorafenib-treated HCC patients and evaluated miR-22 effects in the DEN-HCC rat model. Moreover, I reported miR-22 as a promising circulating biomarker of TACE response. I also demonstrated WEE1 targeting by miR-22 and the involvement of miR-22/WEE1 axis in cell proliferation, apoptosis and DNA damage following doxorubicin treatment under hypoxia-like conditions.
Collectively, these data highlight the potential role of CXCL3, miR-30e-3p and miR-22 as circulating biomarkers of sorafenib response. Furthermore, miR-22 emerged as an early circulating biomarker of TACE nonresponse while the miR-22/WEE1 axis represents an interesting therapeutic target for combined strategies.
Tipologia del documento
Tesi di dottorato
Autore
Vianello, Clara
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
38
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
HCC, microRNA, sorafenib, TACE, biomarker
Data di discussione
15 Luglio 2026
URI
Altri metadati
Tipologia del documento
Tesi di dottorato
Autore
Vianello, Clara
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
38
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
HCC, microRNA, sorafenib, TACE, biomarker
Data di discussione
15 Luglio 2026
URI
Gestione del documento: